Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly diagnosed...

Full description

Saved in:

Bibliographic Details
Published in:	Blood cancer journal (New York) Vol. 13; no. 1; pp. 112 - 8
Main Authors:	Tan, Carlyn Rose, Derkach, Andriy, Nemirovsky, David, Ciardiello, Amanda, Diamond, Benjamin, Hultcrantz, Malin, Hassoun, Hani, Mailankody, Sham, Shah, Urvi, Maclachlan, Kylee, Patel, Dhwani, Lahoud, Oscar B., Landau, Heather J., Chung, David J., Shah, Gunjan L., Scordo, Michael, Giralt, Sergio A., Lesokhin, Alexander, Usmani, Saad Z., Landgren, Ola, Korde, Neha
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 25.07.2023 Springer Nature B.V Nature Publishing Group
Subjects:	692/699/1541/1990/804 692/700/565/1436/1437 Antineoplastic Combined Chemotherapy Protocols - adverse effects Biomedical and Life Sciences Biomedicine Bortezomib - adverse effects Cancer Research Dexamethasone - therapeutic use Hematology Humans Immunotherapy Induction Chemotherapy Inhibitor drugs Lenalidomide - therapeutic use Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Oncology Retrospective Studies Steroids Targeted cancer therapy
ISSN:	2044-5385, 2044-5385
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!